|
|
Experience of Professor Han Yanhua in the diagnosis and treatment of maternal-fetal blood group incompatibility#br# |
LIU Xiaofang1 HAN Yanhua1 SU Meng2 WANG Qingyi1 |
1.The First Clinical Medical College, Heilongjiang University of Chinese Medicine, Heilongjiang Province, Harbin 150040, China;
2.Department of Gynecology and Obstetrics, Ordos Hospital of Traditional Chinese Medicine, Inner Mongolia Autonomous Region, Ordos 017000, China |
|
|
Abstract The national traditional Chinese medicine master Professor Han Yanhua has enriched experience in maternal-fetal blood group incompatibility, and believes that maternal-fetal blood group incompatibility is mainly the syndrome of root deficiency and tip excess. Deficiency of spleen and kidney, thoroughfare vessel and conception vessel malnutrition, dereliction of duty in storage are root; steaming of humid, hot, and toxin are tip. For this disease, the remaining evils should be eliminated before pregnancy, the damage should be pre-treated, and the disease should be prevented first; treating disease and tranquilizing fetus to prevent miscarriage should be carried out in early pregnancy, invigorating kidney and spleen and tranquilizing fetus to prevent miscarriage, and clearing damp-heat at the same time; late pregnancy is mainly to clear damp-heat, accompanied by activating blood and resolving stasis. This article combines Professor Han Yanhua’s diagnosis and treatment of maternal-fetal blood group incompatibility cases, expounds Professor Han Yanhua’s academic thoughts and clinical ideas for differentiation and treatment of the disease, prescriptions and medications, in order to inspire clinical diagnosis and treatment.
|
|
|
|
|
[1] 姚庆民.血液系统疾病诊治思路与治疗策略[M].长春:吉林科学技术出版社,2017:110.
[2] Christensen RD,Baer VL,MacQueen BC,et al. ABO hemolytic disease of the fetus and newborn: thirteen years of data after implementing a universal bilirubin screening and manage-ment program [J]. Perinatol,2018;38(5):517-525.
[3] Yigit S,Gursoy T,Kanra T,et al. Whole blood versus red cells and plasma for exchange transfusion in ABO haemolytic disease [J]. Transfus Med,2005,15(4):313-318.
[4] Akgül S,Korkmaz A,Yi■it S,et al. Neonatal hyperbilirubinemia due to ABO incompatibility:does blood group matter? [J]. Pediatr,2013,55(5):506-509.
[5] 田兆嵩.临床输血学[M].2版.北京:人民卫生出版社,2002:178.
[6] 陈明,陈小鹤,曾珏,等.母婴ABO血型不合新生儿溶血病的临床与实验室研究[J].中华全科医学,2018,16(10):1680-1682.
[7] 孙悦玲,孙红格,施选性,等.孕期夫妇血型血清学检测与新生儿溶血病关系的探讨[J].中国优生与遗传杂志,2006,14(2):2.
[8] 高志峰,胡丽华,余忠清.374例孕妇产前IgG抗体测定[J].临床血液学杂志,2004,17(3):169.
[9] 马晓露.孕母血型抗体与新生儿ABO溶血病发生的相关性分析[J].中国实验诊断学,2009,13(12):1744-1746.
[10] 谢梦潇,王欣.母儿Rh血型不合孕期监测研究进展[J].中国计划生育学杂志,2021,29(7):1532-1538.
[11] 张趁利,庞桂芝,娄白敏.孕妇产前血型抗体效价与新生儿溶血病的检测结果分析[J].临床血液学杂志(输血与检验),2018,31(2):124-126.
[12] 魏建波,秦斐,王伟,等.孕妇产前ABO和Rh血型抗体检测结果分析[J].中国卫生检验杂志,2012,22(4):806-808.
[13] 王冬梅,董伟群,邹映东,等.2580例O型孕妇IgG抗A抗B血型抗体效价检测分析[J].昆明医科大学学报,2014,35(10):119-121.
[14] 徐佳新,许浚,曹勇,等.中药白芍现代研究进展及其质量标志物的预测分析[J].中国中药杂志,2021,46(21):10.
[15] 张新轩.菟丝子的药学研究进展[J].海峡药学,2021,33(3):56-59.
[16] 高宏伟,李玉萍,李守超.杜仲的化学成分及药理作用研究进展[J].中医药信息,2021,38(6):73-81.
[17] 李佳欣,陈思琦,葛鹏玲.山茱萸药理学研究进展[J/OL].辽宁中医药大学学报:1-15[2021-09-01].http://kns.cnki.net/kcms/detail/21.1543.R.20210623.1438.002.html.
[18] 杨迎迎,万新焕,刘英男,等.垂盆草化学成分及药理作用研究进展[J].中国中药杂志,2020,45(18):4341-4348.
[19] Schutz E,Fischer A,Beck J,et al. Graft-derived cell-free DNA,a noninvasive early rejection and graft damage marker in liver transantation:A prospective,observational,multicenter cohort study [J]. PLoS Med,2017,14(4):e1002286.
[20] Thurik FF,Ait Soussan A,Bossers B,et al. Analysis of false-positive results of fetal RHD typing in a national screening program reveals vanishing twins as potential cause for discrepancy [J]. Prenat Diagn,2015,35(8):754-760.
[21] Wang M,Hays T,Ambruso DR,et al. Hemolytic disease of the newborn caused by a high titer anti-group B IgG from a group A mother [J]. Pediatr Blood Cancer,2005, 45(6):861-862.
[22] 杨传英.中医药经典方药治疗ABO母儿血型不合临床应用探讨[J].中国医药导报,2013,10(11):91-93.
[23] 撒元红,孙振高,肖继梅,等.茵陈蒿汤加减分阶段治疗母儿ABO血型不合的应用进展研究[J].时珍国医国药,2018,29(6):1423-1425.
[24] 焦素芬,孙绍静,班小娟,等.复方丹参注射液联合硫酸镁对子痫前期患者胎盘循环的影响[J].中国药业,2021, 30(5):45-47.
[25] 杨映映,唐浚峰,李青伟,等.炭类中药药理研究及临床应用[J].辽宁中医药大学学报,2020,22(10):186-190. |
|
|
|